Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a virtual fireside chat scheduled for Wednesday, February 12, 2025, at 12:40 pm ET.
Interested parties can access a live webcast of the presentation through the Events and Presentations section on Protara's investor relations website at https://ir.protaratx.com. The presentation recording will be available for a time following the event.
Protara Therapeutics (Nasdaq: TARA), un'azienda in fase clinica focalizzata sullo sviluppo di terapie per il cancro e le malattie rare, ha annunciato la sua prossima partecipazione alla 35a Conferenza Annuale sulla Salute e le Scienze della Vita di Oppenheimer. La gestione dell'azienda parteciperà a una chiacchierata virtuale programmata per mercoledì 12 febbraio 2025, alle 12:40 ora ET.
Le parti interessate possono accedere a una diretta web della presentazione attraverso la sezione Eventi e Presentazioni del sito web delle relazioni con gli investitori di Protara all'indirizzo https://ir.protaratx.com. La registrazione della presentazione sarà disponibile per un certo tempo dopo l'evento.
Protara Therapeutics (Nasdaq: TARA), una empresa en fase clínica centrada en el desarrollo de terapias para el cáncer y enfermedades raras, ha anunciado su próxima participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La dirección de la empresa participará en un chat virtual programado para miércoles, 12 de febrero de 2025, a las 12:40 p.m. ET.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Eventos y Presentaciones en el sitio web de relaciones con inversionistas de Protara en https://ir.protaratx.com. La grabación de la presentación estará disponible por un tiempo después del evento.
Protara Therapeutics (Nasdaq: TARA)는 암 및 희귀질환 치료제를 개발하는 임상 단계 회사로, Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 참석할 예정이라고 발표했습니다. 회사의 경영진은 2025년 2월 12일 수요일 오후 12:40 ET에 예정된 가상 대화에 참여할 것입니다.
관심 있는 분들은 Protara의 투자자 관계 웹사이트 https://ir.protaratx.com의 이벤트 및 발표 섹션을 통해 발표의 생중계를 확인할 수 있습니다. 발표 녹화는 이벤트 후 일정 기간 동안 제공될 예정입니다.
Protara Therapeutics (Nasdaq: TARA), une entreprise en phase clinique axée sur le développement de thérapies contre le cancer et les maladies rares, a annoncé sa prochaine participation à la 35ème Conférence Annuelle sur la Santé et les Sciences de la Vie d'Oppenheimer. La direction de l'entreprise participera à un chat virtuel prévu pour mercredi 12 février 2025, à 12h40 ET.
Les parties intéressées peuvent accéder à une diffusion en direct de la présentation via la section Événements et Présentations sur le site des relations avec les investisseurs de Protara à l'adresse suivante : https://ir.protaratx.com. L'enregistrement de la présentation sera disponible pendant un certain temps après l'événement.
Protara Therapeutics (Nasdaq: TARA), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien gegen Krebs und seltene Erkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der 35. Jahrestagung für Gesundheits- und Lebenswissenschaften von Oppenheimer angekündigt. Das Management des Unternehmens wird an einem virtuellen Gespräch teilnehmen, das für Mittwoch, den 12. Februar 2025, um 12:40 Uhr ET geplant ist.
Interessierte Parteien können über den Bereich Veranstaltungen und Präsentationen auf der Investor-Relations-Website von Protara unter https://ir.protaratx.com auf den Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird für eine gewisse Zeit nach der Veranstaltung zur Verfügung stehen.
- None.
- None.
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 12:40 pm ET.
A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When is Protara Therapeutics (TARA) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Protara Therapeutics' (TARA) Oppenheimer Conference presentation?
Will Protara Therapeutics' (TARA) Oppenheimer Conference presentation be available for replay?
What type of presentation will Protara Therapeutics (TARA) give at the Oppenheimer Conference 2025?
